关注
Elias K. Mai
Elias K. Mai
University Hospital Heidelberg
在 med.uni-heidelberg.de 的电子邮件经过验证
标题
引用次数
引用次数
年份
Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling
M Felcht, R Luck, A Schering, P Seidel, K Srivastava, J Hu, A Bartol, ...
The Journal of clinical investigation 122 (6), 1991-2005, 2012
5042012
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
KM Kortüm, EK Mai, NH Hanafiah, CX Shi, YX Zhu, L Bruins, S Barrio, ...
Blood, The Journal of the American Society of Hematology 128 (9), 1226-1233, 2016
2462016
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial
H Goldschmidt, HM Lokhorst, EK Mai, B van der Holt, IW Blau, ...
Leukemia 32 (2), 383-390, 2018
2172018
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma
EK Mai, U Bertsch, J Dürig, C Kunz, M Haenel, IW Blau, M Munder, ...
Leukemia 29 (8), 1721-1729, 2015
2012015
Angiopoietin-2 is critical for cytokine-induced vascular leakage
AV Benest, K Kruse, S Savant, M Thomas, AM Laib, EK Loos, U Fiedler, ...
PloS one 8 (8), e70459, 2013
1982013
Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project
M D'agostino, DA Cairns, JJ Lahuerta, R Wester, U Bertsch, A Waage, ...
Journal of clinical oncology 40 (29), 3406-3418, 2022
1872022
Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation
J Xu, N Pfarr, V Endris, EK Mai, NH Md Hanafiah, N Lehners, R Penzel, ...
Oncogenesis 6 (5), e337-e337, 2017
872017
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial
M Merz, H Salwender, M Haenel, EK Mai, U Bertsch, C Kunz, T Hielscher, ...
haematologica 100 (7), 964, 2015
792015
Application of 18F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities
C Sachpekidis, J Mosebach, MT Freitag, T Wilhelm, EK Mai, ...
American journal of nuclear medicine and molecular imaging 5 (5), 479, 2015
772015
Single versus tandem high‐dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long‐term results from the phase III …
EK Mai, A Benner, U Bertsch, P Brossart, A Hänel, V Kunzmann, ...
British journal of haematology 173 (5), 731-741, 2016
722016
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG …
H Goldschmidt, EK Mai, U Bertsch, R Fenk, E Nievergall, D Tichy, ...
The Lancet Haematology 9 (11), e810-e821, 2022
592022
A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma
EK Mai, T Hielscher, JK Kloth, M Merz, S Shah, MS Raab, M Hillengass, ...
Haematologica 100 (6), 818, 2015
572015
Analysis of long‐term survival in multiple myeloma after first‐line autologous stem cell transplantation: impact of clinical risk factors and sustained response
N Lehners, N Becker, A Benner, M Pritsch, M Löpprich, EK Mai, ...
Cancer medicine 7 (2), 307-316, 2018
522018
Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology
EK Mai, T Hielscher, JK Kloth, M Merz, S Shah, M Hillengass, B Wagner, ...
European radiology 26, 3939-3948, 2016
472016
Search for familial clustering of multiple myeloma with any cancer
C Frank, M Fallah, T Chen, EK Mai, J Sundquist, A Försti, K Hemminki
Leukemia 30 (3), 627-632, 2016
472016
18F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate
C Sachpekidis, EK Mai, H Goldschmidt, J Hillengass, D Hose, L Pan, ...
Clinical nuclear medicine 40 (6), e300-e307, 2015
472015
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial
H Goldschmidt, EK Mai, J Dürig, C Scheid, KC Weisel, C Kunz, U Bertsch, ...
Leukemia 34 (7), 1853-1865, 2020
462020
Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma
M Merz, T Hielscher, A Seckinger, D Hose, EK Mai, MS Raab, ...
American journal of hematology 91 (11), E473-E477, 2016
422016
A systematic classification of death causes in multiple myeloma
EK Mai, EM Haas, S Lücke, M Löpprich, C Kunz, M Pritsch, ...
Blood cancer journal 8 (3), 30, 2018
362018
Elotuzumab in combination with lenalidomide, bortezomib, dexamethasone and autologous transplantation for newly-diagnosed multiple myeloma: results from the randomized phase …
H Goldschmidt, EK Mai, U Bertsch, B Besemer, M Haenel, K Miah, R Fenk, ...
Blood 138, 486, 2021
322021
系统目前无法执行此操作,请稍后再试。
文章 1–20